Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunocore Holdings plc IMCR

Healthcare Biotechnology
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and... see more

Recent & Breaking News (NDAQ:IMCR)

Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 10, 2021

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

GlobeNewswire November 9, 2021

Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel

GlobeNewswire October 18, 2021

Immunocore announces publication of phase 3 data comparing tebentafusp with investigator's choice in The New England Journal of Medicine

GlobeNewswire September 22, 2021

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

GlobeNewswire September 20, 2021

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

GlobeNewswire September 13, 2021

Immunocore to present at upcoming investor conferences

GlobeNewswire September 10, 2021

Immunocore Announces UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

GlobeNewswire September 8, 2021

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

GlobeNewswire August 24, 2021

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 11, 2021

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 4, 2021

Immunocore to present at upcoming investor conferences

GlobeNewswire May 27, 2021

Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

GlobeNewswire May 18, 2021

Immunocore Reports First Quarter 2021 Financial Results

GlobeNewswire May 12, 2021

Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 28, 2021

Immunocore presents phase 3 data comparing tebentafusp with investigator's choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting

GlobeNewswire April 12, 2021

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

GlobeNewswire March 25, 2021

Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting

GlobeNewswire March 10, 2021

Immunocore's tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA

GlobeNewswire February 19, 2021